NASDAQ:ALRN Aileron Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.24 -0.02 (-7.69%) (As of 07/1/2022 01:54 PM ET) Add Compare Share Today's Range$0.23▼$0.2550-Day Range$0.26▼$0.5452-Week Range$0.32▼$1.34Volume57,379 shsAverage Volume318,405 shsMarket Capitalization$21.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALRN Stock Forecast (MarketRank)Overall MarketRank™1.67 out of 5 starsMedical Sector948th out of 1,429 stocksPharmaceutical Preparations Industry472nd out of 682 stocksAnalyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Aileron Therapeutics has a forecasted upside of 1,204.3% from its current price of $0.23.Amount of Analyst CoverageAileron Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesAileron Therapeutics has received 210 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAileron Therapeutics has received 104 “underperform” votes. (Add your “underperform” vote.)Community SentimentAileron Therapeutics has received 66.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote “Outperform” if you believe ALRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 37.06% of the stock of Aileron Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to remain at ($0.38) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aileron Therapeutics (NASDAQ:ALRN)Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.Read More ALRN Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comAileron Therapeutics (NASDAQ:ALRN) Price Target Lowered to $1.00 at HC WainwrightJuly 1, 2022 | marketwatch.comAileron Therapeutics Shares Down After Lung Cancer DataJune 30, 2022 | americanbankingnews.comAileron Therapeutics (NASDAQ:ALRN) Downgraded to "Market Perform" at William BlairJune 29, 2022 | tmcnet.comAileron Therapeutics Announces Interim Data from Phase 1bJune 29, 2022 | finance.yahoo.comAileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer SettingJune 29, 2022 | seekingalpha.comAileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trialJune 29, 2022 | finance.yahoo.comAileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast CancerJune 13, 2022 | americanbankingnews.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 39.6%June 13, 2022 | americanbankingnews.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 39.6% in MayMay 19, 2022 | seekingalpha.comAileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapyMay 19, 2022 | finance.yahoo.comAileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast CancerMay 17, 2022 | finance.yahoo.comAileron Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | finance.yahoo.comAileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees9Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/01/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+1,150.0%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.300010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.30% Return on Assets-54.13% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.50Miscellaneous Outstanding Shares90,824,000Free Float88,281,000Market Cap$21.80 million OptionableNot Optionable Beta2.50 Aileron Therapeutics Frequently Asked Questions Should I buy or sell Aileron Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Aileron Therapeutics stock. View analyst ratings for Aileron Therapeutics or view top-rated stocks. What is Aileron Therapeutics' stock price forecast for 2022? 3 brokerages have issued 1-year price targets for Aileron Therapeutics' stock. Their ALRN stock forecasts range from $1.00 to $5.00. On average, they expect Aileron Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price. View analysts' price targets for Aileron Therapeutics or view top-rated stocks among Wall Street analysts. How has Aileron Therapeutics' stock price performed in 2022? Aileron Therapeutics' stock was trading at $0.5629 on January 1st, 2022. Since then, ALRN shares have decreased by 57.4% and is now trading at $0.24. View the best growth stocks for 2022 here. When is Aileron Therapeutics' next earnings date? Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Aileron Therapeutics. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its earnings results on Thursday, May, 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. View Aileron Therapeutics' earnings history. Who are Aileron Therapeutics' key executives? Aileron Therapeutics' management team includes the following people: Dr. Manuel C. Aivado, Pres, CEO & Director (Age 52, Pay $912.38k)Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 55, Pay $574.22k)Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 49) Who are some of Aileron Therapeutics' key competitors? Some companies that are related to Aileron Therapeutics include Ardelyx (ARDX), Cue Biopharma (CUE), Fortress Biotech (FBIO), Hookipa Pharma (HOOK), Sol-Gel Technologies (SLGL), Clearside Biomedical (CLSD), Enlivex Therapeutics (ENLV), Pyxis Oncology (PYXS), Merrimack Pharmaceuticals (MACK), HCW Biologics (HCWB), Vicapsys Life Sciences (VICP), Alzamend Neuro (ALZN), MEI Pharma (MEIP), Synlogic (SYBX) and Galectin Therapeutics (GALT). View all of ALRN's competitors. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV). When did Aileron Therapeutics IPO? (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What is Aileron Therapeutics' stock symbol? Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN." How do I buy shares of Aileron Therapeutics? Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aileron Therapeutics' stock price today? One share of ALRN stock can currently be purchased for approximately $0.24. How much money does Aileron Therapeutics make? Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $21.80 million. The company earns $-26.16 million in net income (profit) each year or ($0.300010) on an earnings per share basis. How many employees does Aileron Therapeutics have? Aileron Therapeutics employs 9 workers across the globe. How can I contact Aileron Therapeutics? Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for Aileron Therapeutics is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at [email protected]. This page (NASDAQ:ALRN) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
